Results 61 to 70 of about 24,360 (218)

Incidentally detected Castleman disease in a patient with allergic rhinosinu sitis [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2008
INTRODUCTION Castleman disease was for the first time described in 1956 as a mediastinal tumour mass. Etiology of this disease is still unknown. The disease can be solitary and multicentric or rarely of a mixed type.
Stojšić Jelena, Krstić Svetlana, Subotić Dragan, Eminović Tatjana, Radojičić Jelena   +4 more
doaj   +1 more source

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.

The Lancet Haematology, 2020
BACKGROUND Siltuximab is recommended by international consensus as a first-line treatment for idiopathic multicentric Castleman disease on the basis of durable efficacy and safety data.
F. van Rhee, C. Casper, P. Voorhees, L. Fayad, D. Gibson, K. Kanhai, R. Kurzrock   +6 more
semanticscholar   +1 more source

Potential of Ginkgo biloba Extract to Intervene in Chronic Inflammation‐Related Diseases

Phytotherapy Research, EarlyView.
Chronic inflammation is a pathological mechanism underpinning many diseases. Ginkgo biloba extract (GBE) is well known for its anti‐inflammatory property. GBE and its active constituents have been shown to attenuate pro‐inflammatory cytokine production, suppress nuclear factor kappa B activation, restore redox homeostasis, and modulate disease‐relevant
Yipeng Lin, Inho Cho, Xue Zhu, Ke Wang, Ling Zhu, Wenchang Wong, Michael Murray, Fanfan Zhou   +7 more
wiley   +1 more source

2007-2008 Master Class - Charles Castleman (Violin) [PDF]

, 2007
Charles Castleman Performance (October 6, 2007) - Programhttps://spiral.lynn.edu/conservatory_masterclasses/1115/thumbnail ...
Wei, Xinou, Lin, Tao, Chernova, Elena, Zhang, Dongfang, Castleman, Charles, Lee, Seul-A, Johnson, Gareth   +6 more
core  

Increased mTOR activation in idiopathic multicentric Castleman disease.

Blood, 2020
Idiopathic multicentric Castleman disease (iMCD) is a rare and poorly-understood hematologic disorder characterized by lymphadenopathy, systemic inflammation, cytopenias, and life-threatening multi-organ dysfunction.
Daniel J. Arenas, Katherine Floess, D. Kobrin, R. Pai, M. Srkalovic, M. Tamakloe, R. Rasheed, Jasira Ziglar, J. Khor, Sophia A. T. Parente, S. Pierson, D. Martinez, G. Wertheim, T. Kambayashi, Joseph A. Baur, D. Teachey, D. Fajgenbaum   +16 more
semanticscholar   +1 more source

Long‐Term Outcomes After Elective Splenectomy for Haematological Disease: A 27‐Year Single‐Centre Study

ANZ Journal of Surgery, EarlyView.
Splenectomy is a safe and effective treatment option in selected patients with haematological disease, despite declining referrals over the last 27 years in the era of targeted therapies. Outcomes are favourable when performed laparoscopically and long‐term follow‐up demonstrates sustained haematologic benefit in surviving patients.
Salil Dutt Barrett, Anthony Downhill, Douglas Greer, William Stevenson, Ian Kerridge, Chris Ward, Matthew Greenwood, Naomi Mackinlay, Luke Coyle, Thomas J. Hugh   +9 more
wiley   +1 more source

Maladie de castleman multicentrique: A propos d’un cas [PDF]

, 2010
La maladie de Castleman est une affection rare, d’étiologie inconnue, caractérisée sur le plan histologique par une hyperplasie lymphoïde angiofolliculaire. Elle se présente sous deux formes différentes, localisée et multicentrique.
M Belcadhi, I Riahi, Bouzouita, K, M Abdelkefi, Khlif, A, I Zeglaoui, R Mani, Abdelkefi, M, Mani, R, A Khlif, Zeglaoui, I, Bellakhdher, M, Sriha, B, B Ali, Riahi, I, Belcadhi, M, B Sriha, K Bouzouita, Ali, B, M Bellakhdher   +19 more
core   +1 more source

The management of Castleman disease

British Journal of Haematology, 2021
Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, Guys and St, Thomas’ NHS Foundation Trust, Kings College Hospital NHS Foundation Trust, London, Department of Haematology, University Hospitals Birmingham NHS ...
O. Lomas, M. Streetly, G. Pratt, J. Cavet, D. Royston, S. Schey, K. Ramasamy   +6 more
semanticscholar   +1 more source

Early tocilizumab and outcomes in acute necrotizing encephalopathy

Developmental Medicine &Child Neurology, EarlyView.
Early tocilizumab and outcome in acute necrotising encephalopathy. Aim To evaluate the timing and safety of tocilizumab in acute necrotizing encephalopathy (ANE). Method This was a multicentre retrospective study evaluating outcomes (modified Rankin Scale [mRS]) in children with ANE treated with tocilizumab. A logistic regression model determined a cut‐
Velda X Han, Prithuja Poudyal, Vanessa Lee, Arushi Gahlot Saini, Shekeeb S Mohammad, Sekhar C Pillai, Gouri Rao Passi, Naveen Sankhyan, Ahmad Rithauddin Mohamed, Lokesh Lingappa, Hiroshi Sakuma, Russell C Dale, Ming Lim, Terrence Thomas, for The International ANE Study Group   +14 more
wiley   +1 more source

Systemic lupus erythematosus mimicking idiopathic multicentric Castleman disease: A diagnostic dilemma

SAGE Open Medical Case Reports, 2022
Castleman disease is a heterogeneous group of disorders of lymphoid tissue. It can often mimic other autoimmune diseases or malignancies, presenting a diagnostic dilemma to attending clinicians.
KUIS Gunathilake, MIM Rifath, BM Munasinghe, P Muhunthiny, Gayana Vincent   +4 more
doaj   +1 more source